Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
While tolvaptan provides therapeutic benefits, it poses a risk of significant adverse reactions. Clinicians should closely monitor the occurrence of events related to hepatobiliary disorders, renal and urinary disorders, metabolic and nutritional disorders, as well as benign, malignant, and indeterminate tumors during its clinical use.
Authors
- Liyuan Yan (ORCID: https://orcid.org/0009-0007-0802-4348)
- Peiyang Cao
- Qian Wang (ORCID: https://orcid.org/0000-0002-4541-9898)
- Qing Qiao (ORCID: https://orcid.org/0000-0002-2549-6415)
- Yan Wang (ORCID: https://orcid.org/0000-0002-5695-7907)
Institutions
- Nantong University (CN)
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
- Changshu No.1 People's Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-01-09
- DOI
- https://doi.org/10.3389/fphar.2024.1509310
- Citations
- 6
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 7.84